Investor Relations

192

26

COMPOUNDS

TARGETS

66.7%

MDL-001

HIT RATE

LEAD-ASSET

Featured
Model Medicines Reveals Breakthrough AI Discovery: RdRp Thumb-1, A Universal RNA Antiviral Target, and MDL-001, a Potent Inhibitor
Pre-Print
Model Medicines Reveals Breakthrough AI Discovery: RdRp Thumb-1, A Universal RNA Antiviral Target, and MDL-001, a Potent Inhibitor
Pre-Print

Model Medicines is proud to announce the publication of our first preprint, "ChemPrint: An AI-Driven Framework for Enhanced Drug Discovery," now available on bioRxiv.

Read More →
Pre-Print

// About Model Medicines

Innovating at the Intersection of Data Science, Biology and Drug Development

Model Medicines is an AI-driven, human health company using AI to model all of chemistry and human biology, to accelerate the creation of life-changing drugs.

The company was founded in 2019 to deliver on the promise of AI-Drug discovery. With more than 192 compounds for 26 targets, they are delivering on the promise of AI-drug discovery. The company has developed a robust pipeline of patent-pending therapeutics for oncology, infectious diseases, gastric disorders, neurological disorders, and weight disorders.

The company is based in La Jolla, CA.

// Invested in our Success

We’re backed by leading, multi-stage investors with significant expertise and sophistication in the Bio-IT/pharma space.

Featured
8VC
Irving Investors
Thermopolis Partners
ParticleX
Friedman BioVentures
Nex Cubed

// Papers

// UPCOMING AND RECENT Events

// Press Releases